AR068020A1 - Terapia combinada para el cancer de pancreas usando un peptido antigenico y un agente quimioterapeutico - Google Patents
Terapia combinada para el cancer de pancreas usando un peptido antigenico y un agente quimioterapeuticoInfo
- Publication number
- AR068020A1 AR068020A1 ARP080103679A ARP080103679A AR068020A1 AR 068020 A1 AR068020 A1 AR 068020A1 AR P080103679 A ARP080103679 A AR P080103679A AR P080103679 A ARP080103679 A AR P080103679A AR 068020 A1 AR068020 A1 AR 068020A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- peptide
- amino acid
- group
- leucine
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 12
- 239000002246 antineoplastic agent Substances 0.000 title abstract 3
- 229940127089 cytotoxic agent Drugs 0.000 title abstract 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 title abstract 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 title abstract 2
- 208000008443 pancreatic carcinoma Diseases 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 150000001413 amino acids Chemical group 0.000 abstract 6
- 229940024606 amino acid Drugs 0.000 abstract 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 3
- 229930182817 methionine Natural products 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 125000001433 C-terminal amino-acid group Chemical group 0.000 abstract 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 abstract 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 abstract 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 abstract 2
- 229960005277 gemcitabine Drugs 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 abstract 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 1
- 108010081641 arginyl-phenylalanyl-valyl-prolyl-aspartyl-glycyl-asparagyl-arginyl-isoleucine Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229960000310 isoleucine Drugs 0.000 abstract 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1
- 239000004474 valine Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/852—Pancreas
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95792307P | 2007-08-24 | 2007-08-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR068020A1 true AR068020A1 (es) | 2009-10-28 |
Family
ID=40386893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080103679A AR068020A1 (es) | 2007-08-24 | 2008-08-22 | Terapia combinada para el cancer de pancreas usando un peptido antigenico y un agente quimioterapeutico |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8703713B2 (enExample) |
| EP (1) | EP2195003A4 (enExample) |
| JP (1) | JP5417667B2 (enExample) |
| KR (1) | KR20100047899A (enExample) |
| CN (1) | CN101883577A (enExample) |
| AR (1) | AR068020A1 (enExample) |
| AU (1) | AU2008292966C1 (enExample) |
| BR (1) | BRPI0815726A2 (enExample) |
| CA (1) | CA2697501A1 (enExample) |
| IL (1) | IL204143A (enExample) |
| MX (1) | MX2010002178A (enExample) |
| MY (1) | MY160406A (enExample) |
| NZ (1) | NZ583578A (enExample) |
| RU (1) | RU2472522C2 (enExample) |
| SG (1) | SG183770A1 (enExample) |
| TW (1) | TWI436775B (enExample) |
| UA (1) | UA100702C2 (enExample) |
| WO (1) | WO2009028150A1 (enExample) |
| ZA (1) | ZA201001580B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1548032T1 (sl) | 2002-09-12 | 2009-10-31 | Oncotherapy Science Inc | KDR peptidi in cepiva, ki obsegajo le-te |
| US20080034017A1 (en) * | 2006-08-04 | 2008-02-07 | Dominic Giampaolo | Links to a common item in a data structure |
| TW201109029A (en) * | 2009-06-11 | 2011-03-16 | Oncotherapy Science Inc | Vaccine therapy for choroidal neovascularization |
| EP2578233B1 (en) | 2010-05-28 | 2017-04-26 | National Cancer Center | Therapeutic agent for pancreatic cancer |
| DE102013214023B4 (de) * | 2013-07-17 | 2015-02-12 | Siemens Aktiengesellschaft | Verfahren zu einem Auswerten und Vergleichen von zeitlich aufeinander folgenden kombinierten medizinischen Bildgebungsuntersuchungen sowie ein medizinisches Bildgebungssystem, das zu einem Ausführen des erfindungsgemäßen Verfahrens ausgelegt ist |
| ES2927366T3 (es) * | 2014-10-09 | 2022-11-04 | Univ Yamaguchi | Vector de expresión de CAR y células T que expresan CAR |
| KR20230004907A (ko) * | 2014-10-14 | 2023-01-06 | 립타이드 바이오사이언스, 인코포레이티드 | 항-염증 특성을 갖는 펩타이드 |
| US20200147194A1 (en) * | 2017-05-19 | 2020-05-14 | Keio University | Peptide vaccine and peptide vaccine composition for cranial nerve disease |
| US10413584B1 (en) | 2018-08-29 | 2019-09-17 | Riptide Bioscience, Inc. | Peptides having immunomodulatory properties |
| US10548944B1 (en) | 2018-10-19 | 2020-02-04 | Riptide Bioscience, Inc. | Antimicrobial peptides and methods of using the same |
| CN114959031A (zh) * | 2022-05-20 | 2022-08-30 | 上海交通大学医学院附属瑞金医院 | 胰腺腺癌预后评估的标志物组合及其应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB213645A (en) | 1922-12-22 | 1924-03-24 | Frank Lincoln Morse | Improvements in and relating to chain and sprocket wheel gearing |
| US3265572A (en) | 1961-09-20 | 1966-08-09 | S B Penick And Company | Process for preparing tyrociding and product produced thereby |
| US4526988A (en) | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
| DK0694042T3 (da) | 1993-03-25 | 2005-02-14 | Merck & Co Inc | Inhibitor af vaskulær endothelcellevækstfaktor |
| US6080728A (en) | 1996-07-16 | 2000-06-27 | Mixson; A. James | Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy |
| DE19638745C2 (de) | 1996-09-11 | 2001-05-10 | Schering Ag | Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR) |
| WO1998031794A1 (fr) | 1997-01-17 | 1998-07-23 | Toa Gosei Co., Ltd. | Polypeptide liant le facteur vegf |
| AU2299099A (en) | 1998-02-04 | 1999-08-23 | Kyowa Hakko Kogyo Co. Ltd. | Antibodies against human vegf receptor kdr |
| GB9804121D0 (en) | 1998-02-26 | 1998-04-22 | Cancer Res Campaign Tech | Anti-angiogenic vaccines: materials and methods relating thereto |
| EP1086705A4 (en) | 1998-05-20 | 2002-02-06 | Kyowa Hakko Kogyo Kk | INHIBITORS OF THE ACTIVITY OF THE VASCULAR ENDOTHELIAL GROWTH FACTOR |
| US7087411B2 (en) * | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US7264810B2 (en) | 2001-01-19 | 2007-09-04 | Cytos Biotechnology Ag | Molecular antigen array |
| CU23178A1 (es) * | 2002-04-15 | 2006-09-22 | Ct Ingenieria Genetica Biotech | INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA |
| SI1548032T1 (sl) | 2002-09-12 | 2009-10-31 | Oncotherapy Science Inc | KDR peptidi in cepiva, ki obsegajo le-te |
| AU2003291726A1 (en) | 2002-11-04 | 2004-06-07 | Xenoport, Inc. | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof |
| WO2005087808A2 (en) * | 2004-03-05 | 2005-09-22 | Ludwig Institute For Cancer Research | Growth factor binding constructs materials and methods |
| RU2006146619A (ru) * | 2004-06-03 | 2008-07-20 | Ф.Хоффманн-Ля Рош Аг (Ch) | Лечение гемцитабином и ингибитором рецептора эпидермального фактора роста(egfr) |
| ES2310860T3 (es) | 2004-12-17 | 2009-01-16 | Eli Lilly And Company | Profarmaco amida de gemcitabina, composiciones y uso del mismo. |
| US20060216288A1 (en) | 2005-03-22 | 2006-09-28 | Amgen Inc | Combinations for the treatment of cancer |
| PL2119447T3 (pl) | 2007-02-16 | 2013-08-30 | Oncotherapy Science Inc | Terapia szczepionkowa przeciwko neowaskularyzacji naczyniówkowej |
-
2008
- 2008-08-13 TW TW097130789A patent/TWI436775B/zh not_active IP Right Cessation
- 2008-08-19 BR BRPI0815726A patent/BRPI0815726A2/pt not_active IP Right Cessation
- 2008-08-19 EP EP08828542A patent/EP2195003A4/en not_active Withdrawn
- 2008-08-19 MY MYPI2010000779A patent/MY160406A/en unknown
- 2008-08-19 KR KR1020107005967A patent/KR20100047899A/ko not_active Ceased
- 2008-08-19 CN CN2008801133893A patent/CN101883577A/zh active Pending
- 2008-08-19 JP JP2010506728A patent/JP5417667B2/ja not_active Expired - Fee Related
- 2008-08-19 UA UAA201002881A patent/UA100702C2/ru unknown
- 2008-08-19 WO PCT/JP2008/002232 patent/WO2009028150A1/en not_active Ceased
- 2008-08-19 RU RU2010111139/15A patent/RU2472522C2/ru not_active IP Right Cessation
- 2008-08-19 NZ NZ583578A patent/NZ583578A/en not_active IP Right Cessation
- 2008-08-19 US US12/674,754 patent/US8703713B2/en not_active Expired - Fee Related
- 2008-08-19 AU AU2008292966A patent/AU2008292966C1/en not_active Ceased
- 2008-08-19 SG SG2012063046A patent/SG183770A1/en unknown
- 2008-08-19 MX MX2010002178A patent/MX2010002178A/es active IP Right Grant
- 2008-08-19 CA CA2697501A patent/CA2697501A1/en not_active Abandoned
- 2008-08-22 AR ARP080103679A patent/AR068020A1/es unknown
-
2010
- 2010-02-24 IL IL204143A patent/IL204143A/en not_active IP Right Cessation
- 2010-03-04 ZA ZA2010/01580A patent/ZA201001580B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL204143A (en) | 2013-04-30 |
| MX2010002178A (es) | 2010-03-18 |
| RU2472522C2 (ru) | 2013-01-20 |
| MY160406A (en) | 2017-03-15 |
| TW200914037A (en) | 2009-04-01 |
| AU2008292966C1 (en) | 2013-03-14 |
| ZA201001580B (en) | 2011-02-23 |
| SG183770A1 (en) | 2012-09-27 |
| JP5417667B2 (ja) | 2014-02-19 |
| US20110082088A1 (en) | 2011-04-07 |
| KR20100047899A (ko) | 2010-05-10 |
| NZ583578A (en) | 2012-07-27 |
| CN101883577A (zh) | 2010-11-10 |
| BRPI0815726A2 (pt) | 2016-01-05 |
| CA2697501A1 (en) | 2009-03-05 |
| US8703713B2 (en) | 2014-04-22 |
| WO2009028150A1 (en) | 2009-03-05 |
| AU2008292966A1 (en) | 2009-03-05 |
| EP2195003A1 (en) | 2010-06-16 |
| UA100702C2 (ru) | 2013-01-25 |
| JP2010536714A (ja) | 2010-12-02 |
| EP2195003A4 (en) | 2011-07-06 |
| AU2008292966B2 (en) | 2012-07-19 |
| RU2010111139A (ru) | 2011-09-27 |
| TWI436775B (zh) | 2014-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR068020A1 (es) | Terapia combinada para el cancer de pancreas usando un peptido antigenico y un agente quimioterapeutico | |
| CO6190536A2 (es) | Vacunas peptidicas para canceres que expresan antigenos asociados con tumores | |
| CO6260151A2 (es) | Peptido de cdh3 y agente medicinal que comprende al mismo | |
| CL2019003404A1 (es) | Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico.(divisional solicitud 201702407) | |
| RU2013112616A (ru) | Пептид cdca1 и включающее его фармацевтическое средство | |
| HRP20160020T1 (hr) | Postupak za aktiviranje pomagaäśke t stanice i pripravak za uporabu u postupku | |
| CL2021000549A1 (es) | Péptido asociado a tumor (tumap); ácido nucleico; vector de expresión; célula hospedadora recombinante que comprende el péptido; método para producir el péptido; composición farmaceutica; uso para preparar un medicamento útil para tratar el cáncer; kit farmacéutico (divisional de la solicitud no. 201900460) | |
| HRP20110242T1 (hr) | Formulacija s fuzijskim proteinom glp-1-fc | |
| AR064555A1 (es) | Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo | |
| PE20240015A1 (es) | Proteinas de fusion gdf15 y usos de estas | |
| AR070276A1 (es) | Composicion que comprende anticuerpo que se fija al dominio ii de her2 y sus variantes acidas. formulacion farmaceutica. usos. metodo de preparacion. | |
| PE20130579A1 (es) | Composiciones y metodos para suministro al sistema nervioso central de iduronato-2-sulfatasa | |
| AR076349A1 (es) | Peptido auxiliar del antigeno del cancer | |
| PE20191716A1 (es) | Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos | |
| JP2010536714A5 (enExample) | ||
| RU2013131089A (ru) | Пептиды тем8 и содержащие их вакцины | |
| CL2020003293A1 (es) | Péptido que consiste en la secuencia de aminoácidos de seq id no: 42; anticuerpo que reconoce dicho péptido; receptor de linfocito t; célula hospedadora; linfocito t activado; composición farmacéutica; uso; y kit (divisional de la solicitud no. 201802969) | |
| CN106232616A (zh) | 两亲性合成抗菌肽、其药物组合物及其用途 | |
| JP2025121987A (ja) | Ｇｌｐ－１／ｇｌｐ－２デュアルアゴニストの医薬組成物 | |
| CN116710114B9 (zh) | Glp-1/glp-2双重激动剂的药物组合物 | |
| AR071774A1 (es) | Sal de acetato de un compuesto peptidico que tiene actividad antitumoral y su uso. | |
| ES2723098T3 (es) | Agonistas del péptido CRHR2 y usos de los mismos | |
| CO6260086A2 (es) | Combinacion farmaceutica que comprende peptidos derivados de vegfr2 y gemcitabina, una sal de ella o una prodroga de ella | |
| JP2016535600A5 (enExample) | ||
| JP7809117B2 (ja) | Ｇｌｐ－１／ｇｌｐ－２デュアルアゴニストの医薬組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |